| |
著者: Hanno H Leuchte, Rainer A Baumgartner, Michal El Nounou, Michael Vogeser, Claus Neurohr, Michael Trautnitz, Juergen Behr
雑誌名: Am J Respir Crit Care Med. 2006 Apr 1;173(7):744-50. doi: 10.1164/rccm.200510-1545OC. Epub 2006 Jan 13.
Abstract/Text
RATIONALE: The detection of pulmonary hypertension in patients with chronic lung disease has prognostic implications. The brain natriuretic peptide (BNP) has been suggested as a noninvasive marker for the presence and severity of pulmonary hypertension.
OBJECTIVES: We evaluated circulating BNP levels as a parameter for the presence and severity of pulmonary hypertension in patients with chronic lung disease.
METHODS: BNP levels were measured in 176 consecutive patients with various pulmonary diseases. Right heart catheterization, lung functional testing, and a 6-min walk test were performed. The mean follow-up time was nearly 1 yr.
MEASUREMENTS AND MAIN RESULTS: Significant pulmonary hypertension (mean pulmonary artery pressure > 35 mm Hg) was diagnosed in more than one-fourth of patients and led to decreased exercise tolerance and life expectancy. Elevated BNP concentrations identified significant pulmonary hypertension with a sensitivity of 0.85 and specificity of 0.88 and predicted mortality. Moreover, BNP served as a risk factor of death independent of lung functional impairment or hypoxemia in uni- and multivariate analysis.
CONCLUSION: We suggest BNP as a prognostic marker and as screening parameter for significant pulmonary hypertension in chronic lung disease.
PMID 16415273 Am J Respir Crit Care Med. 2006 Apr 1;173(7):744-50. doi: 10.1164/rccm.200510-1545OC. Epub 2006 Jan 13.
|
